Oppenheimer Raises Target on Cubist Pharmaceuticals (CBST) On Advancing Pipeline, Cubicin Growth Trajectory
Tweet Send to a Friend
Oppenheimer lifted its price target on Outperform-rated Cubist Pharmaceuticals (NASDAQ: CBST) from $49 to $55.
The firm comments, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
The firm comments, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
